Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.70 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.70 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801558 | 1.00 | P2RY10 (0.70) | P2RY10GPR34GPR174 | |
| SCHEMBL1800150 | 0.94 | P2RY10 (0.73) | P2RY10GPR34GPR174 | |
| SCHEMBL15928070 | 0.87 | P2RY10 (0.72) | P2RY10GPR34GPR174 | |
| SCHEMBL15927983 | 0.87 | P2RY10 (0.72) | P2RY10GPR34GPR174 | |
| SCHEMBL19941696 | 0.87 | P2RY10 (0.72) | P2RY10GPR34GPR174 | |
| Dexfosfoserine SCHEMBL28465640 | 0.85 | ENPP2 (0.70) | P2RY10GPR34GPR174 | |
| Dexfosfoserine SCHEMBL28767573 | 0.85 | ENPP2 (0.70) | P2RY10GPR34GPR174 | |
| 1,2-Dipalmitin SCHEMBL21382909 | 0.85 | ENPP2 (0.70) | P2RY10GPR34GPR174 | |
| Phosphatidyl Serine SCHEMBL24802704 | 0.85 | P2RY10 (0.75) | P2RY10GPR34GPR174 | |
| SCHEMBL22531350 | 0.85 | P2RY10 (0.75) | P2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202040-B2 | Method for screening compounds which change the binding properties of a protein with a ligand | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-10 | — | — | US | claimed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20230181466-A1 | BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230038598-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-02-09 | — | — | US | disclosed |
| EP-3858332-A1 | BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-08-04 | — | — | EP | disclosed |
| EP-3838266-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED INTRACELLULAR CARGO DELIVERY | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020252365-A1 | SYSTEMS AND METHODS TO PREDICT INCREASED RISK FOR ADVERSE CARDIOVASCULAR EVENTS IN HUMAN IMMUNODEFICIENCY VIRUS (HIV)-INFECTED SUBJECTS | BLOODWORKS (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20130028963-A1 | Forming an Artificial Cell with controlled membrane composition, asymmetry, and contents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | disclosed |
| US-7951548-B2 | IL-13 production inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090170116-A1 | IL-13 Production Inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1852503-A1 | IL-13 PRODUCTION INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7202040-B2 | Method for screening compounds which change the binding properties of a protein with a ligand | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-10 | — | — | US | disclosed |
| US-20050154190-A1 | Screening method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1455186-A1 | SCREENING METHOD | Takeda Chemical Industries, Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-5739274-A | COMPRISING POLYPEPTIDE LINKED TO PHOSPHOLIPID; PRODUCES DELAYED INCREASE IN BLOOD PRESSURE, INCREASE IN EXTRACELLULAR CALCIUM UPTAKE BY VASCULAR SMOOTH MUSCLE | CV TECHNOLOGIES, INC. (CA) | 1998-04-14 | — | — | US | disclosed |
| EP-0644895-A1 | ACTIVE COMPONENT OF PARATHYROID HYPERTENSIVE FACTOR | CV TECHNOLOGIES, INC. (CA) | 1995-03-29 | — | — | EP | disclosed |
| WO-1993025577-A2 | ACTIVE COMPONENT OF PARATHYROID HYPERTENSIVE FACTOR | ZENYAKU KOGYO CO., LTD. (JP) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230038598-A1 | MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY | PCNA, BOD1L1, SARS1 | P2RY10 4008/4885GPR34 1785/4885GPR174 2120/4885 |
| US-20050154190-A1 | Screening method | SLC6A19, SLC1A5, SLC7A1 | P2RY10 3424/4885GPR34 429/4885GPR174 2731/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | P2RY10 1923/4885GPR34 3566/4885GPR174 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.